Jiangsu Wanbang Biopharmaceuticals (hereinafter referred to as “Wanbang Biopharma”), a subsidiary of Fosun Pharma recently signed an agreement with Zaozhuang Ruicheng Biochemical Co., Ltd (hereinafter referred to as “Ruicheng”) in Xuzhou. Under the contract, Wanbang acquired 51% shares of Zaozhuang Sainuokang Biochemical Co., Ltd (hereinafter referred to as “Sainuokang”) from Ruicheng.
Pharmaceutical manufacturing is the core business in Fosun Pharma’s strategy. Since 2002, Fosun Pharma has been committed to the development, manufacturing and distribution of pharmaceutical products involving 5 largest and fastest-growing therapeutic fields: metabolism & alimentary tract, cardiovascular system, oncology, central nervous system and anti-infection. As the key subsidiary of Fosun Pharma, Wanbang Biopharma upholds development strategy of “Focusing on diabetic drugs, developing in cardiovascular and anti-tumour fields”. Statistics from IMS shows that Wanbang Biopharma has become the largest heparin sodium injection manufacturer and a leading low molecular heparin injection manufacturer in China. However, without manufacturing approval of herparin API, Wanbang Biopharma has to purchase the API from outside for manufacturing the finished product, which brings high risks and challenges in fierce market competition due to the lack of control to quality and cost.


Heparin is extracted from porcine intestinal mucosa and is the best-selling and widely-used anti-coagulant drug in the world. It is widely used for prevention and treatment of thrombosis, unstable angina pectoris and acute myocardial infarction, etc., and prevention of blood clots during dialysis and transfusion. China is a major producer and exporter of heparin sodium API in the world. Heparin sodium API takes an important position in China pharmaceutical export earnings.


Sainuokang is a professional manufacturer of heparin sodium API. Through adopting new manufacturing process, it takes the leading position in technology and cost effectiveness in the country. “Through strategic cooperation with Ruicheng, Wanbang Biopharma holds the major stake of Sainuokang, which is helpful to secure supply of heparin sodium API and reduce purchasing cost,” said Li Xianlin, senior Vice President of Fosun Pharma & Chairman of Pharmaceutical Industry Management Committee. “In addition, Fosun Pharma will help Sainuokang introduce advanced concept and system of quality management to improve the quality of product and create favorable conditions to develop the global market of heparin sodium API.”